Acute Rhabdomyolysis as a Complication of Interferon Treatment for Stage IIIc Melanoma

Abstract

Background: Interferon alfa-2b is a treatment option for select patients with stage 3 melanoma. Objective: To highlight the potential complication of acute rhabdomyolysis from interferon alfa-2b in this patient population. Methods: We present a case of a 63-year-old female with stage IIIc melanoma who developed acute rhabdomyolysis after completing 2 of 4 weeks of induction with high-dose interferon alfa-2b. She recovered after hydration with intravenous fluids and discontinuation of interferon alfa-2b. Results: Review of the literature revealed eight cases of reported rhabdomyolysis triggered by interferon use, including four cases of melanoma. Conclusion: In patients treated with interferon, especially at high doses, screening for creatine kinase and myoglobinuria should be performed if the patient develops symptoms suggestive of acute rhabdomyolysis.